Review article · 2019 · Open access

The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach

Giuseppe Nicotera, Gianluca Sferrazza, Annalucia Serafino, Pasquale Pierimarchi

Frontiers in Medicine, 6, 148 · Published 27 June 2019 · DOI 10.3389/fmed.2019.00148

Open PDFView at the publisherCite this paper

In brief

“The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach” is a 2019 review article by Giuseppe Nicotera and 3 co-authors, published in Frontiers in Medicine. OpenAlex counts 28 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Medicine.

Citations
28
Most cited in
2020 (6)
Field-weighted impact
0.88
References
25
Authors
4

Abstract

The development of novel regulatory tools such as adaptive clinical trial design and utilization of real-world evidence are topics of high interest. Recently, the European Medicines Agency (EMA) introduced the Adaptive Pathways (AP) that represents an innovative tool in healthcare systems allowing the early dialogue with multiple stakeholders on promising and innovative medicinal products in areas with an high unmet medical need. The innovative aspect in the AP is the early involvement of several stakeholders such as pharmaceutical industry, the Academia, Health Technology Assessment (HTA) bodies, and patient representatives bringing their real experience with the disease and their expectations about the treatment. AP is not a new licensing tool but an opportunity for a very early discussions, before starting the phase II studies, among all stakeholders, including regulators, companies, HTA bodies, and patient representatives on a new potential medicine in areas of high unmet medical need. The aim of this paper is to describe the evolution of the AP approach from the beginning of the pilot project to date, highlighting major advances, and achievement at European level.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Nicotera, G., Sferrazza, G., Serafino, A., & Pierimarchi, P. (2019). The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach. Frontiers in Medicine, 6, 148. https://doi.org/10.3389/fmed.2019.00148

MLA 9

Nicotera, Giuseppe, et al. “The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach.” Frontiers in Medicine, vol. 6, 2019, p. 148. https://doi.org/10.3389/fmed.2019.00148.

Chicago

Nicotera, Giuseppe, Gianluca Sferrazza, Annalucia Serafino, and Pasquale Pierimarchi. 2019. “The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach.” Frontiers in Medicine 6: 148. https://doi.org/10.3389/fmed.2019.00148.

Harvard

Nicotera, G. et al. (2019) ‘The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach’, Frontiers in Medicine, 6, p. 148. doi:10.3389/fmed.2019.00148.

IEEE

G. Nicotera, G. Sferrazza, A. Serafino, and P. Pierimarchi, “The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach,” Frontiers in Medicine, vol. 6, p. 148, 2019, doi: 10.3389/fmed.2019.00148.

BibTeX

@article{nicotera2019iterative,
  title     = {{The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach}},
  author    = {Nicotera, Giuseppe and Sferrazza, Gianluca and Serafino, Annalucia and Pierimarchi, Pasquale},
  journal   = {Frontiers in Medicine},
  year      = {2019},
  volume    = {6},
  pages     = {148},
  doi       = {10.3389/fmed.2019.00148},
  url       = {https://doi.org/10.3389/fmed.2019.00148}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201911
202066
202166
202222
202322
202422
202544
202655

Its field-weighted citation impact is 0.88: it has been cited 0.88 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation

  • adaptive pathways
  • European Medicines Agency
  • adaptive trial design
  • real-world evidence
  • drug regulation
  • health technology assessment
  • patient representatives
  • unmet medical needs

Work with this paper

Most-cited papers in Nursing

All highly cited Nursing papers

Questions about this paper

How do I cite this paper in APA style?

Nicotera, G., Sferrazza, G., Serafino, A., & Pierimarchi, P. (2019). The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach. Frontiers in Medicine, 6, 148. https://doi.org/10.3389/fmed.2019.00148

How many times has this paper been cited?

28 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Giuseppe Nicotera, Gianluca Sferrazza, Annalucia Serafino, Pasquale Pierimarchi.

What is the DOI of this paper?

10.3389/fmed.2019.00148, permanently at https://doi.org/10.3389/fmed.2019.00148. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.